Targeting pathological B cell receptor signalling in lymphoid malignancies

Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110d, in patients with previously treated chronic lymphocytic leukemia.

(2017) S. E. Coutre et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathogenesis of Human B Cell Lymphomas

(2012) Arthur L. Shaffer et al.   Annual Review of Immunology

Germinal Centers

(2012) Gabriel D. Victora et al.   Annual Review of Immunology

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances

(2012) Lomon So et al.   BIOCHEMICAL JOURNAL

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

(2012) A. Agathangelidis et al.   BLOOD

Self-antigen recognition by follicular lymphoma B-cell receptors

(2012) K. L. Sachen et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

MYD88 somatic mutations in MALT lymphomas

(2012) Zhi-Ming Li et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis

(2012) Sandrine Sander et al.   CANCER CELL

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

(2012) C. Renner et al.   HAEMATOLOGICA

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

(2012) Anne Pham-Ledard et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

(2012) Marcus Dühren-von Minden et al.   NATURE

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

(2012) Roland Schmitz et al.   NATURE

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

(2011) Manuel Montesinos-Rongen et al.   ACTA NEUROPATHOLOGICA

Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

(2011) A. Hadzidimitriou et al.   BLOOD

SYK inhibition and response prediction in diffuse large B-cell lymphoma

(2011) S. Cheng et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype

(2011) Francisco J. Hernandez-Ilizaliturri et al.   CANCER

Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-Cell Lymphomas

(2011) T. L. Naylor et al.   CANCER RESEARCH

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2011) P. C. Amrein et al.   CLINICAL CANCER RESEARCH

The B-cell antigen receptor signals through a preformed transducer module of SLP65 and CIN85

(2011) Thomas Oellerich et al.   EMBO JOURNAL

Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape

(2011) Margrith E Mattmann et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas

(2011) Q. Yan et al.   HAEMATOLOGICA

Monophosphorylation of CD79a and CD79b ITAM Motifs Initiates a SHIP-1 Phosphatase-Mediated Inhibitory Signaling Cascade Required for B Cell Anergy

(2011) Shannon K. O'Neill et al.   IMMUNITY

Selective Utilization of Toll-like Receptor and MyD88 Signaling in B Cells for Enhancement of the Antiviral Germinal Center Response

(2011) Baidong Hou et al.   IMMUNITY

Anergic Responses Characterize a Large Fraction of Human Autoreactive Naive B Cells Expressing Low Levels of Surface IgM

(2011) T. D. Quach et al.   JOURNAL OF IMMUNOLOGY

The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma

(2011) P Ruminy et al.   LEUKEMIA

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

(2011) Víctor Quesada et al.   NATURE GENETICS

Malignant pirates of the immune system

(2011) Lixin Rui et al.   NATURE IMMUNOLOGY

SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia

(2011) Lili Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Malt1-dependent RelB cleavage promotes canonical NF- B activation in lymphocytes and lymphoma cell lines

(2011) S. Hailfinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling

(2010) M. Suljagic et al.   BLOOD

PI3K/p110  is a novel therapeutic target in multiple myeloma

(2010) H. Ikeda et al.   BLOOD

Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities

(2010) F. Marcucci et al.   BLOOD

Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin

(2010) C. C. Chu et al.   BLOOD

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

Origin of Chromosomal Translocations in Lymphoid Cancer

(2010) André Nussenzweig et al.   CELL

Molecular underpinning of B-cell anergy

(2010) Yuval Yarkoni et al.   IMMUNOLOGICAL REVIEWS

Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses

(2010) N. S. Zuckerman et al.   INTERNATIONAL IMMUNOLOGY

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

(2010) T E Witzig et al.   LEUKEMIA

Receptors, subcellular compartments and the regulation of peripheral B cell responses: The illuminating state of anergy

(2010) Marcus R. Clark et al.   MOLECULAR IMMUNOLOGY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Oligomeric organization of the B-cell antigen receptor on resting cells

(2010) Jianying Yang et al.   NATURE

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

Critical role of PI3K signaling for NF- B-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells

(2010) B. Kloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins

(2010) V. Coelho et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression

(2010) J. M. Irish et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The PI3K Isoforms p110  and p110  Are Essential for Pre-B Cell Receptor Signaling and B Cell Development

(2010) F. Ramadani et al.   Science Signaling

PKC  is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC  as a therapeutic target in chronic lymphocytic leukemia

(2009) C. Holler et al.   BLOOD

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406

(2009) M. P. Quiroga et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

Suppression of Phosphatidylinositol 3,4,5-Trisphosphate Production Is a Key Determinant of B Cell Anergy

(2009) Cecille D. Browne et al.   IMMUNITY

The molecular assembly and organization of signaling active B-cell receptor oligomers

(2009) Pavel Tolar et al.   IMMUNOLOGICAL REVIEWS

Tyrosine kinases and their substrates in B lymphocytes

(2009) Tomohiro Kurosaki et al.   IMMUNOLOGICAL REVIEWS

Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

(2009) Abdalla J. Mohamed et al.   IMMUNOLOGICAL REVIEWS

Multiple layers of B cell memory with different effector functions

(2009) Ismail Dogan et al.   NATURE IMMUNOLOGY

Essential function for the GTPase TC21 in homeostatic antigen receptor signaling

(2009) Pilar Delgado et al.   NATURE IMMUNOLOGY

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma

(2009) S. Hailfinger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing

(2008) George R. Clemens et al.   BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

(2008) R. M. Young et al.   BLOOD

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

(2008) S Gobessi et al.   LEUKEMIA

Unknown

(2008) Rosa Catera et al.   MOLECULAR MEDICINE

T cell antigen receptor stimulation induces MALT1 paracaspase–mediated cleavage of the NF-κB inhibitor A20

(2008) Beatrice Coornaert et al.   NATURE IMMUNOLOGY

The proteolytic activity of the paracaspase MALT1 is key in T cell activation

(2008) Fabien Rebeaud et al.   NATURE IMMUNOLOGY

Is NF-κB a good target for cancer therapy? Hopes and pitfalls

(2008) Véronique Baud et al.   NATURE REVIEWS DRUG DISCOVERY

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

(2008) G. Lenz et al.   SCIENCE

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

(2007) F. Morschhauser et al.   ANNALS OF ONCOLOGY